Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for KRAS G12C-mutant pancreatic ductal adenocarcinoma, drawn from the whole corpus: 11 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Responses to G12C-selective inhibitors are shallower and shorter in the pancreas than in the lung.
Neither sotorasib nor adagrasib has a pancreatic indication, so access depends on off-label use and trials.
Whether adding a G12C-selective drug to a pan-RAS inhibitor improves on the pan-RAS drug alone is untested.
The group is too small for large randomised trials of its own.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
OS 13.
A milestone in how this cancer is treated.
Objective response 21 percent (8 of 38; 95 percent confidence interval 10 to 37); median progression-free survival 4.
Pancreatic cancer cohort: objective response in 7 of 21 patients (33.
A milestone in how this cancer is treated.